WEIR monoclonal antibody contract
Past New Requirement Updated
- Agency
-
Food and Drug Administration
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $10,000 to $25,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Points of contact
-
- CBER Acquisition Liaison cbera.acquisitions@fda.hhs.gov
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The Food and Drug Administration (FDA) is seeking strain-specific influenza monoclonal antibodies for the development of alternative potency assays for pandemic influenza vaccines. This new requirement contract is estimated for solicitation release on April 1, 2026, with an anticipated award date of May 1, 2026. The procurement falls under biotechnology research and development services and does not utilize any small business set-asides.
The estimated contract award value ranges from $10,000 to $25,000. Interested contractors should direct inquiries to the FDA's Center for Biologics Evaluation and Research (CBER) Acquisitions team at cbera.acquisitions@fda.hhs.gov for additional information regarding technical specifications and submission requirements.
Forecast text
WEIR monoclonal antibody contract. Strain specific influenza monoclonal antibodies are needed for development alternative potency assays for pandemic influenza vaccines.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast